#LCSM Chat topic 6/14/2018: Immunotherapy–the ultimate personalized therapy

Immunotherapy has revolutionized cancer care, particularly for lung cancer patients.  On Thursday, June 14, 2018, at 8 PM Eastern time (5 PM Pacific), #LCSM Chat moderator Brendon Stiles (@BrendonStilesMD) will lead our discussion on “Immunotherapy–the ultimate personalized therapy.” Over the last few years, several “checkpoint inhibitors” have been approved by the FDA for lung cancer patients.  Because these drugs essentially unleash brakes on T cells which allow each patient’s own immune system to kill their cancer cells, these drugs could be considered the ultimate personalized therapy for cancer.  In fact, these drugs… Read More

#LCSM Chat 5/31/18: Lung Cancer at ASCO 2018

For the upcoming #LCSM chat on Thursday, 5/31 at 8 PM Eastern (5 PM Pacific), we’re going to preview some of the key abstracts in lung cancer and mesothelioma that will be presented at the American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago in early June. This meeting brings together over 38,000 cancer specialists every year to review thousands of presentations. Nobody can see it all, and one important aspect of not being overwhelmed is knowing what should be the focus of your attention. Dr. Jack West has compiled two… Read More

#LCSM Chat Topic 5/3/18:  What Defines a “Quality” #LungCancer Treatment Center?  Thoughts from the Frontline

Our topic for the #LCSM Tweet Chat on Thursday, May 3rd (5 PM Pacific/8 PM Eastern) is “What Defines a “Quality” #LungCancer Treatment Center?  Thoughts from the Frontline.” The moderator for this chat is Dr. David Tom Cooke (@DavidCookeMD). Recently the Centers for Medicaid and Medicare Services (CMS) announced it would cover next-generation sequencing (NGS) for US patients with stage III or IV lung cancer when ordered by a physician and performed in a CLIA-certified laboratory.  This decision makes broad genomic testing to available to many more patients.  Having increased access to… Read More